...Cunliang Zhu; Zhaobi Fang; Lei Peng; Fan Gao; Wei Peng; Fengqian Song Background: Irinotecan (IRI) is a common chemotherapeutic drug for colorectal cancer; however, the mechanism underlying its immunomodulatory effect remains unclear. Curcumin (CUR), an adjuvant drug with anti-inflammatory...

...Ching-Wen Huang; Yung-Sung Yeh; Cheng-Jen Ma; Hsiang-Lin Tsai; Chao-Wen Chen; Ming-Yii Huang; Chien-Yu Lu; Jeng-Yih Wu; Jaw Yuan Wang Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line...

...) following combination therapy with bevacizumab (BVZ) and irinotecan among patients with relapsed glioblastoma. Safety data will also be reviewed and all results will be compared with data of the literature. Methods: In this single-center retrospective study, all records of patients treated with BVZ...

...Wenna Wang; Jing Huang; Yunxia Tao; Xiao Lyu; Lin Yang; Dawei Wu; Yantao Tian Background: We investigated the efficacy and safety of biweekly irinotecan and cisplatin (IP) as first-line treatment in advanced gastric cancer patients. Methods: Irinotecan 125 mg/m 2 on day 1 and cisplatin 60 mg/m 2...

... of irinotecan and S-1 (IRIS) as a second-line treatment for colorectal cancer (CRC). Methods: S-1 was administered on days 1-14 of a 28-day cycle. Irinotecan was administered on days 1 and 15. The irinotecan dose was then escalated to determine the maximum-tolerated dose and the recommended dose at a fixed...

...K. Eichler; T. Dufas; R. Hammerstingl; T. Gruber-Rouh; T.J. Vogl; S. Zangos Background: To define the maximum tolerated dose (MTD) tolerability and efficacy of intra-arterial chemotherapy with irinotecan in patients with liver metastases of colorectal carcinoma (CRC). Methods: Superselective intra...

...Simon J. Crabb; Jennifer Bradbury; Luke Nolan; Diana Selman; Sethupathi R. Muthuramalingam; Judith Cave; Peter W.M. Johnson; Christian Ottensmeier Background: Treatment options for small cell lung cancer (SCLC) remain inadequate. Irinotecan has been tested in various combinations with platinum...

... II trial was to evaluate the efficacy and safety of a combination therapy with gemcitabine and irinotecan as the first-line chemotherapy in patients with previously untreated advanced BTC. Patients and Methods: Patients with pathologically confirmed advanced BTC received gemcitabine (1,000 mg/m 2...

...J. Feliu Batlle; E. Cuadrado; J. Castro; T. Caldés; C. Belda; J. Sastre; J. Barriuso; V. Martínez Marín; E. Díaz-Rubio; M. González-Barón Background: The objective was to evaluate the efficacy of irinotecan-cetuximab-bevacizumab in combination as a salvage treatment for heavily pretreated...

... events that occur in mucositis. As this method relies on the use of a validated endogenous control, this study aims to validate commonly used housekeeping genes in an irinotecan-induced mucositis model. Methods: Rats were administered irinotecan and sacrificed at different time points, in particular 1...

... for growth of human tumor cells in vitro, and (2) to determine the effect of the anticancer agent irinotecan on the cystine transporter x c – in head and neck FaDu xenografts. Methods: Cell growth was measured by sulforhodamine B assay. xCT protein, glutathione (GSH) and DNA damage were determined using...

... Yubero; Luis Cirera Background: We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. Methods: 126 patients from 19 centers were included from July 2006 to July 2007 in this prospective non-controlled study. Irinotecan-refractory metastatic...

... of pegylated liposomal doxorubicin and irinotecan in patients with previously treated solid tumors. Results: Twelve patients were enrolled. The median age was 62 years (range 19–72). The most common grade 3/4 toxicities were neutropenia (dose-limiting toxicity), diarrhea and nausea/vomiting. The maximal...

...: Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m 2 , followed by leucovorin (LV) 20 mg/m 2 and 5-fluorouracil (5-FU) 500 mg/m 2 administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m 2 /day with LV 30 mg/day on days 1–22...

... and irinotecan reduced treatment-related toxicity and improved efficacy via the preferential delivery of irinotecan to the tumor and lymph nodes. This study was designed as a first-in-man investigation of the safety and pharmacokinetics of irinotecan when administered within the HA-Irinotecan formulation...

...Sotaro Sadahiro; Toshiyuki Suzuki; Yuji Maeda; Kenji Ishikawa; Seiei Yasuda; Hiroyasu Makuuchi; Chieko Murayama Background: To evaluate the efficacy and safety of irinotecan combined with UFT for untreated and pretreated metastatic colorectal cancer. Methods: Escalating doses of irinotecan (80–110...

...Shinichiro Akiyama; Hidetsugu Nakayama; Hiroya Takami; Hiromichi Gotoh; Yoshikazu Gotoh Objective: Combination therapy with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin is widely used for the treatment of metastatic colorectal cancer. However, little is known about the safety...

...Rachel J. Gibson; Joanne M. Bowen; Enrique Alvarez; John Finnie; Dorothy M.K. Keefe Background: Irinotecan is a common cytotoxic agent used in advanced colorectal cancers. However, a major clinical problem with this cytotoxic is that it causes gastrointestinal mucositis manifest by severe diarrhoea...

... of the present study was to evaluate the differences in the sequence of administration of 5-fluorouracil (5-FU)/leucovorin (LV) followed by irinotecan (CPT-11), or CPT-11 followed by 5-FU/LV in advanced colorectal cancer (ACC). Patients and Methods: Chemotherapy-naïve patients with ACC were allocated...

...Masao Ichiki; Rumi Gohara; Toru Rikimaru; Takao Kitajima; Rei Fujiki; Akiko Shimada; Hisamichi Aizawa This phase II study was conducted to investigate the efficacy and safety of irinotecan (CPT-11) and ifosfamide as second-line chemotherapy for relapsed small cell lung cancer (SCLC). Eligibility...